IceCure Medical Gains NMPA Approval for Cryoablation Technology in China
Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s...
Cancer
ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...
Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer
China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab),...
ImmuneOnco Achieves Full Enrollment in Phase II Study of IMM01 for CMML
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the successful completion of patient enrollment in its...
Shenzhen Hepalink’s OncoVent Secures Licensing Deal with Orient EuroPharma for Oregovomab
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has...
Kintor Pharmaceutical Realigns Funds from COVID-19 Studies to Other Pipeline Candidates
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced a strategic change in the allocation of...
Shanghai Pharmaceuticals’ SPH4336 Earns Orphan Drug Status for Liposarcoma Treatment
Shanghai Pharmaceuticals, a leading pharmaceutical company based in China (HKG: 2607, SHA: 601607), has announced...
Junshi Biosciences and Rxilient Biotech Form JV to Commercialize Tuoyi in Southeast Asia
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV)...
CDE Grants Priority Review Status to TQB3454, HLX208, and Infigratinib for Cancer Treatments
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQB3454, Henlius...
Berry Genomics Partners with MGI Tech to Advance Cancer Diagnostics and Screening
Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary...
BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda
Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with...
CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008
Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a...
CDE Launches Technical Guidelines for Pediatric Anti-tumor Drug Development
The Center for Drug Evaluation (CDE) has released a set of Technical Guidelines focused on...
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Gain Clinical Trial Approvals
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...
Akeso Biopharma and LaNova Medicines Collaborate on Clinical Studies for Cancer Therapies
China-based Akeso Biopharma (HKG: 9926) has announced a strategic partnership with fellow Chinese firm LaNova...
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Secure Clinical Trial Approvals for Solid Tumors
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...
Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors
China-based Akeso Biopharma (HKG: 9926) has entered into a strategic partnership with compatriot firm LaNova...
CDE Launches Technical Guidelines for Pediatric Anti-tumor Drug Clinical R&D
The Center for Drug Evaluation (CDE) has released a set of Technical Guidelines focused on...
Sihuan Pharmaceutical’s KM501 Receives Clinical Trial Approval for HER2-Positive Tumors
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...
Alphax Bio Raises Millions for Spatial Proteomics and Tumor Immune Microenvironment Research
Beijing-based Alphax Bio, a developer of immune-testing technologies, has reportedly raised “tens of millions” of...